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ABSTRACT
Nasopharyngeal carriage is a major factor in the transmission of pneumococcal disease. The aim of this
study was to determine the prevalence of asymptomatic nasopharyngeal carriage of Streptococcus
pneumoniae and the distribution of serogroups and serotypes in children aged 3–36 months attending
day care centres in Belgium. A single nasopharyngeal swab was cultured from 467 children attending 30
different day care centres between December 2000 and March 2001. S. pneumoniae isolates were
serotyped and their antibiotic susceptibilities assessed by disk diffusion. The overall nasopharyngeal
carriage rate for S. pneumoniae was 21% in the 467 children. None of the commonly accepted risk factors
studied was associated significantly with carriage. Capsular serotypes isolated were 19F (27.3%), 6B
(20.2%), 23F (19.2%), 19A (10.1%), 6A (7.1%), 14 (5.1%) and others (11.0%). Theoretical coverage by the
seven-valent (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) pneumococcal conjugate vaccine was 73.7%.
Fourteen (14.1%) of 99 strains were non-susceptible to penicillin, 48 (48.5%) to tetracycline and 61
(61.6%) to erythromycin. Theoretical coverage by the seven-valent pneumococcal conjugate vaccine was
93% for the penicillin-resistant serotypes, 69% for the tetracycline-resistant serotypes and 75% for the
erythromycin-resistant serotypes. Use of the seven-valent pneumococcal conjugate vaccine could
potentially reduce nasopharyngeal carriage of the antibiotic-resistant strains.
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INTRODUCTION
Streptococcus pneumoniae remains a major world-
wide cause of childhood morbidity and mortality.
At least 1 million children die of pneumococcal
infections each year [1]. S. pneumoniae causes a
variety of clinical syndromes, including invasive
infections such as bacteraemia and meningitis, as
well as pneumonia and otitis media, with chil-
dren aged < 2 years being at greatest risk [2].
The main reservoir of pneumococci is the
nasopharynx. Many individuals in a population
are colonised with S. pneumoniae at any given
time, and most children are colonised at some
point during the first 2 years of life [3]. Young
children are frequently colonised for prolonged
periods with the same serotypes [4]. S. pneumoniae
can spread from the nasopharynx to adjacent
mucosae, and can spread easily from the naso-
pharynx of one child to that of another. Naso-
pharyngeal carriage is a major factor in the
horizontal transmission of pneumococcal disease,
especially in children attending day care centres
[5–7]. Only a small percentage of colonised
children will develop an invasive infection, but
pneumococcal nasopharyngeal isolates reflect the
strains currently circulating in the community [8],
and may predict the capsular types of pneumo-
cocci causing invasive disease [9,10].
Pneumococcal resistance to antibiotics is
increasing globally. In Belgium in 2002, the
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recorded resistance rates for invasive S. pneumo-
niae isolates of 15.1% for penicillin (MIC 0.12–
2 mg ⁄L), 30.7% for tetracycline and 36.1% for
erythromycin, with this resistance being more
important in children than in the elderly. Most
studies investigating risk factors for antibiotic
resistance in pneumococci have identified antimi-
crobial use as a major determinant. Other risk
factors for carriage of resistant pneumococci are
young age, attendance at day care centres, and
previous hospitalisation [10].
Studies in Israel and South Africa have shown
that the use of conjugate vaccines in young
children and infants reduces nasopharyngeal
carriage of pneumococci belonging to the capsu-
lar types included in the vaccine [11,12]. Reduc-
tion of carriage may help to control the
transmission of capsular types commonly asso-
ciated with disease (e.g., otitis media) and the
spread of resistant pneumococci in the commu-
nity [9]. To our knowledge, only one single-
centre study has been performed in Belgium
since 1997 on the nasopharyngeal carriage of
S. pneumoniae in children (attending the day care
centre of the University Hospital of Antwerp)
[13]. As a large proportion of small children
attend day care centres in Belgium, the present
study aimed to provide an insight into the
epidemiology, serotype–serogroup distribution
and antibiotic susceptibility patterns of nasopha-
ryngeal strains of S. pneumoniae in a population
of healthy children attending day care centres
throughout Belgium. A second aim was to check
the theoretical efficacy of the seven-valent pneu-
mococcal conjugate vaccine currently available in
Belgium.
MATERIALS AND METHODS
Population
The study enrolled 473 healthy children, aged between
3 months and 3 years, attending 30 day care centres in
Belgium between December 2000 and March 2001. The
children attended 15 different Dutch-speaking centres (belong-
ing to the ‘Kind en Gezin’ network of centres), and 15 French-
speaking centres (belonging to the L’Office de la Naissance et
de l’Enfance (ONE) network). ONE and Kind en Gezin are the
largest providers of day care in Belgium. The centres in the
study were attended by at least 25 children, and were selected
randomly, stratifying for geographical distribution (three
centres in each of the ten Belgian provinces), the population
of the town in which they were located (£ 25 000 or > 25 000),
and the size of the centre (£ 85 or > 85 children).
In each centre, children were screened in alphabetical order
until 17 children per participating centre were obtained. Only
one member per family was included, to avoid bias from
siblings living in the same family environment. Children were
excluded if: they had taken antibiotics in the previous 2 weeks;
they were aged < 3 months or > 36 months; they attended the
centre for < 2 days ⁄week; no informed consent had been
signed by the parents; they suffered from underlying disorders
(e.g., immunological, neoplastic, renal, cardiac, hepatic or
haematological diseases, bronchodysplasia, Down’s syn-
drome, cystic fibrosis); or they were suffering from ongoing
acute upper or lower respiratory tract infection (nasophar-
yngitis, tonsillitis, acute otitis media, laryngitis, tracheobron-
chitis). For the latter group of children, swabs were not taken
until they were clinically cured. Children with rhinitis, but
without fever, were not excluded.
Study procedures
Nurses working in the selected day care centres screened
consecutive children according to the inclusion and exclusion
criteria. If the parents agreed to participate, they were asked to
fill out a questionnaire on the lifestyle and medical history of
their child. Data relating to the following risk factors for
nasopharyngeal carriage were collected: sex, breast-feeding,
ear drains, antibiotic use or respiratory infection in the
previous 6 months, number of siblings, passive smoking, and
size of day care centre. The physician at each day care centre
took a nasopharyngeal swab during routine medical examina-
tion, using a sterile Dracon polyester-tipped applicator (Pur-
itan–Hardwood Products Company LP, Guildford, ME, USA),
as described by the World Health Organization Working
Group for pneumococcal vaccine trials [14]. The collected
swabs were sent the same day by courier to the Belgian
pneumococcal reference laboratory for processing. Question-
naires were validated and amended if necessary by the nurse
or physician.
Laboratory procedures
Identification and storage
Swabs were cultured on brain–heart infusion agar enriched
with horse blood 5% v ⁄v and incubated at 37C for 18–24 h in
CO2 5% v ⁄v. Potential pneumococci were identified by
conventional methods (optochin disk and bile tests) [15]. If
different colony types were observed, each colony type was
examined. All confirmed pneumococci were stored in brain–
heart infusion agar with glycerine at ) 70C [14,15].
Antibiotic susceptibility testing
All pneumococci were tested by disk diffusion with the
National Committee for Clinical Laboratory Standards method
[16] for susceptibility to oxacillin, tetracycline, erythromycin
and ofloxacin. If the zone inhibition diameter for an oxacillin
1-lg disk indicated diminished susceptibility to penicillin
(< 19 mm zone diameter), MICs of penicillin and cefotaxime
were determined by Etests [17].
Serotyping
All strains were tested with pool and group antisera, obtained
from the Statens Seruminstitut (Copenhagen, Denmark). The
Quellung reaction [14] was examined with a phase-contrast
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microscope by experienced laboratory technicians. Non-type-
able strains were subcultured twice on blood agar before
retesting. Subtyping of the serogroups was also performed by
the Statens Seruminstitut.
Statistical analysis
No formal sample size calculation was performed. The number
of subjects included was determined on the basis of the
feasibility of recruitment during the foreseen duration of the
study. With 467 subjects, an event with a prevalence of 24.2%
can be estimated with a precision (standard deviation) of 3.9%
(95% CI 20.3–28.1). Data entry and management were per-
formed by the Data Investigation Company Europe (Brussels,
Belgium). The statistical analysis was mainly descriptive.
Univariate analysis was performed to determine the relative
risk of being a carrier according to different risk factors.
Multivariate analysis was performed to determine independ-
ently significant risk factors for the presence of resistant
S. pneumoniae strains (separately for each of the four anti-
biotics). This analysis makes use of stepwise logistic regres-
sion. Two-tailed tests to determine the significance of risk
factors were performed at the 5% significance level.
Regulatory and ethical aspects
The study was conducted according to the Declaration of
Helsinki as modified by the 48th General Medical Assembly
(October 1996). The protocol was approved by the Ethics
Committee of the ULB Hospital Brussels and the Scientific
Board of ONE. Written informed consent was obtained from
parents or legal guardians in accordance with the guiding
principles of the Declaration of Helsinki.
RESULTS
Day care centres and subject population
On average, a centre cared for 58 children (range
26–107), of whom a mean number of 15 (26.8%)
children ⁄ centre were included in the analysis
(range 4–20). Nine centres included < 17 children
during the recruitment period; data from these
centres were analysed together with data from
other centres. Nine centres were located in a rural
area (£ 25 000 inhabitants), and 21 in a city
(> 25 000 inhabitants). Half of the centres were
linked to Kind en Gezin, and half to ONE.
Of the 473 children included in the study, 467
had complete data sets and could be considered
for statistical analysis. Their demographics and
clinical characteristics are shown in Table 1.
Approximately 50% had been treated with anti-
biotics in the previous 6 months (21% more than
once). Amoxycillin–clavulanic acid (38.4%),
amoxycillin (24%) and cefaclor (23.1%) were the
Table 1. Demographic and clinical
characteristics of children included
in the study Risk factors
Children colonised with
Streptococcus pneumoniae 95% CI
Univariate analysis
RR 95% CI
Sex
Male = 243 54 (22%) (17–27) 1.13 0.79; 1.61
Female = 224 44 (20%) (14–25)
Day care attendance
Full timea = 249 56 (22%) (17–28) 1.17 0.82; 1.67
Part time = 218 42 (19%) (14–24)
Breast-feeding
Yes = 327 73 (22%) (18–27) 1.22 0.81; 1.84
No = 137 25 (18%) (12–25)
Ear drains
Yes = 18 5 (28%) (7–48) 1.34 0.62; 2.87
No = 447 93 (21%) (17–25)
Antibiotics in previous
6 months
Yes = 242 49 (20%) (15–25) 0.92 0.65; 1.30
No = 222 49 (22%) (17–27)
Hospitalisation in previous
6 months
Yes = 47 9 (19%) (8–30) 0.91 0.49; 1.69
No = 415 87 (21%) (17–25)
Respiratory infection in previous
6 months
Yes = 396 81 (20%) (16–24) 0.89 0.56; 1.43
No = 70 16 (23%) (13–33)
Number of siblings
£ 1 = 372 76 (20%) (16–24) 0.86 0.57; 1.31
> 1 = 93 22 (24%) (15–32)
Passive smoking
Yes = 104 18 (17%) (8–21) 0.63 0.40; 1.01
No = 263 80 (30%) (19–28)
Attending day care centre
With < 50 children = 166 33 (20%) (14–26) 0.92 0.63; 1.34
With ‡ 50 children = 301 65 (22%) (17–26)
a4 days ⁄week.
RR, relative risk; 95% CI, 95% confidence interval.
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drugs prescribed most frequently. There was no
difference in previous usage of antibiotics
between children attending centres associated
with ONE or Kind en Gezin.
Recovery of S. pneumoniae from nasopharyngeal
cultures
Overall, 21% of the children were carriers of
S. pneumoniae, with a range of 0–76% among the
centres. Table 2 shows the distribution of differ-
ent serotypes recovered from the nasopharynx;
four serotypes (6B, 19F, 23F and 19A) comprised
76.8% of the isolates. The heptavalent pneumo-
coccal conjugate vaccine Prevenar contains anti-
gens to serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.
Theoretical coverage by this vaccine of the isolates
in this study from healthy children was 73.7%.
Previous studies [18,19] have shown that the
vaccine provides some protection against cross-
reactive or vaccine-related serotypes. Assuming
that serotypes 6A, 19A, 23A and 23B are also
covered by, or cross-reactive with, this vaccine,
the theoretical coverage was 93%. Serogroups 3,
34, 10, 11, 24, 13 and 15 were isolated from 7% of
the cases and are not covered by the vaccine.
The MICs of penicillin-resistant S. pneumoniae
are shown in Table 3. Overall, 14.1% of the
pneumococci showed reduced susceptibility to
penicillin (none of the pneumococci showed
resistance, as the MIC was < 2 mg ⁄L for all
isolates). In addition, 48.5% were resistant to
tetracycline and 61.6% to erythromycin. All
penicillin-non-susceptible isolates, except four,
were susceptible to cefotaxime (MIC £ 0.5 mg ⁄L).
Theoretical coverage by the seven-valent pneu-
mococcal conjugate vaccine was 93% for the
penicillin intermediate-resistant serotypes, 69%
for the tetracycline-resistant serotypes, and 75%
for the erythromycin-resistant serotypes.
Characteristics of S. pneumoniae carriers
Overall, there were no differences between the
characteristics of carriers and non-carriers
(Table 1). There was no difference in the mean
number of oral antibiotic courses in the past
6 months between S. pneumoniae carriers and non-
carriers, even for the high-frequency users. How-
ever, local nasal antibiotics (bacitracin and
neomycin) were used in 16.3% of the carriers vs.
only 4.2% of the non-carriers.
DISCUSSION
In this study, a pneumococcal nasopharyngeal
carriage rate of 21% was found among children
attending day care centres in Belgium. This is
somewhat higher than the prevalence found in
three other studies conducted in Italy in asymp-
tomatic children, in which S. pneumoniae carriage
rates of 3.5% [20], 10.6% [21] and 14.9% [22] were
found. However, the prevalence rate in Belgium
was still much lower than that observed in
children from some other countries, where fre-
quencies have reached 50% [19,23–26]. The
observed carriage was also lower compared to
the only other epidemiological study investi-
gating nasopharyngeal carriage of S. pneumoniae
in Belgium, which found 63 carriers among 100
healthy day care centre attendees aged < 3 years
[13]. In this previous single-centre study, all
specimens were collected in one day care centre
located in a university hospital and attended by
Table 2. Serotypes identified among Streptococcus pneumo-
niae carriers
Serotype Number of isolatesa (%)
19F 27 (27.3)
6B 20 (20.2)
23F 19 (19.2)
19A 10 (10.1
6A 7 (7.1)
14 5 (5.1)
3 1 (1.0)
34 1 (1.0)
23B 1 (1.0)
23A 1 (1.0)
10A 1 (1.0)
18C 1 (1.0)
11A 1 (1.0)
13 1 (1.0)
24F 1 (1.0)
15B 1 (1.0)
9V 1 (1.0)
Total 99 (100)
aOne child was a carrier of two different serotypes.
Table 3. Penicillin G non-susceptible (MIC > 0.06 mg ⁄L)
and cefotaxime-resistant (MIC > 0.5 mg ⁄L) Streptococcus
pneumoniae serotypes
Penicillin
MIC (mg ⁄L) n (%) Serotypes Cefotaxime n (%) Serotypes
0.094 4 (28.6) 6B, 6B, 14, 23F
0.125 0
0.25 2 (14.3) 19F, 23F
0.38 1 (7.1) 19F 1 (25) 19F
0.5 0
0.75 1 (7.1) 23F 2 (50) 23F, 6B
1 4 (28.6) 23F, 6B, 19F, 6A 1 (25) 6A
1.5 2 (14.3) 23F, 23F 0
Total 14 (100) 4 (100)
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children of the hospital personnel. In the present
study, large unexplained differences were seen
between different centres in terms of carriage rate,
with the carriage rate in one centre being as high
as 76%.
Several factors might account for the higher
prevalence rates found in studies from other
countries. First, the geographical and socio-eco-
nomic environment probably has an influence, as
higher rates are observed in less-developed coun-
tries [27,28]. A second factor is the health status of
the younger population examined. For instance,
children with respiratory tract infections are more
likely to be colonised by S. pneumoniae [29]. These
factors did not apply in the present study. A third
possibility is that carriage is often evaluated with
repeated nasopharyngeal sampling over several
months [21,29], whereas the present study used
only a single swab taken during one winter
season.
Only one child carried two pneumococcal
strains, which is low compared to other studies.
However, neither the immunoblot method nor the
serum broth enrichment method was used, both
of which have been shown to improve detection
of multiple serotypes from a cultured specimen,
and are now recommended by the World Health
Organization as standard methods for detecting
upper respiratory carriage of S. pneumoniae
[14,30,31]. A Finnish study compared four tech-
niques for taking nasopharyngeal specimens
(nasal, nasopharyngeal and oropharyngeal swabs,
and nasopharyngeal aspiration) and concluded
that nasopharyngeal aspiration gave the highest
yield [32], but that a nasopharyngeal swab is
optimal for detection of S. pneumoniae and Haemo-
philus influenzae among children aged < 13 months,
particularly when large numbers are being
sampled. The present study used the less invasive
nasopharyngeal swab method [14], which was
perceived by physicians as an easy-to-learn and
ethically justified technique for use with healthy
children. Similar or even lower carriage rates have
been found in other studies using nasopharyngeal
aspiration [20,22].
The present study of healthy children did not
show significant differences between the charac-
teristics of non-carriers and carriers of S. pneumo-
niae, nor were potential risk factors for
nasopharyngeal carriage of S. pneumoniae demon-
strated. According to several previous studies, the
main factors influencing S. pneumoniae carriage
include an age of < 2 years [33], the number of
siblings [21], and overcrowding, including small
living areas and attendance at day care centres,
especially for carriage of resistant strains [20,35].
None of the children in the current study was a
carrier of pneumococci resistant to penicillin
(MIC ‡ 2 mg ⁄L), but 14% of the isolates were
intermediately resistant to penicillin, 48% were
resistant to tetracycline, and 62%were resistant to
erythromycin. These rates are similar for penicil-
lin, but higher for erythromycin, compared to
isolates from invasive infections in the blood and
pleura of children aged < 5 years that were sent to
the Belgian Pneumococcal Reference Laboratory
(mean values in 1998–2000: penicillin, 16%;
erythromycin, 46%). Local nasal antibiotics (baci-
tracin plus neomycin) were used in a larger
proportion of carriers than non-carriers, but no
significant relationship was shown between car-
riage of resistant strains of S. pneumoniae and use
of antibiotics in the previous 6 months.
In a large Canadian study, multiple logistic
regression analysis found that significant risk
factors for carriage of S. pneumoniae resistant to
penicillin, sulphamethoxazole–trimethoprim and
erythromycin were an age of < 24 months and
antibiotic use within the previous month [23]. In
the present study, children who received anti-
bioties in the previous 2 weeks were excluded,
and antibiotic use in the previous 6 months was
checked. To our knowledge, there is no standard-
isation or consensus on the period of antibiotic
use or the antibiotic-free period that should be
taken into account for carriage studies [14].
Theoretical coverage of the serotypes isolated
in the study from healthy children by the seven-
valent pneumococcal conjugate vaccine was
73.7%. The seven serotypes included in the
vaccine account for 81.5% of capsular types
involved in bacteraemia and pleuritis in Belgian
children aged < 5 years, and for 79% of types
involved in meningitis (Belgian Pneumococcal
Reference Laboratory, personal communication).
According to data obtained by capsular typing,
S. pneumoniae serogroup 14 was the predominant
capsular type responsible for invasive infections
in children aged < 5 years in 2000, followed by
capsular types 6 (18.2%) and 19 (14%). These
three S. pneumoniae capsular types were respon-
sible for 55% of invasive infections. In the present
study, the same three types accounted for 69.7%
of the nasopharyngeal isolates from children
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attending day care centres. Capsular type 19 was
responsible for 30% of episodes of S. pneumoniae
otitis media in children aged < 5 years in 1996–
2000 (Belgian Pneumococcal Reference
Laboratory, personal communication), and was
the serotype isolated most frequently in the
present study. The commonest S. pneumoniae
serogroups (19, 14 and 23) accounted for 63% of
all isolates in the nasopharynx of the children
studied. Finally, theoretical coverage in the pre-
sent study by the seven-valent vaccine was high
for the penicillin-non-susceptible serotypes, but
was moderate for the tetracycline- and erythro-
mycin-resistant strains.
In conclusion, asymptomatic nasopharyngeal
carriage was found during one winter season in
21% of healthy children attending Belgian day
care centres, with a varying incidence of carriage
and a high percentage of antibiotic resistance.
No major risk factors for carriage could be
demonstrated. Comparison with other carriage
studies showed a large variation between stud-
ies, which confirmed the need for national
carriage surveillance with standardised methods
[14] to evaluate the effect of the introduction of
conjugate vaccine. Taking into account the
theoretical coverage results, implementation of
these vaccines offer protection against carriage
strains in general, including resistant strains.
This could contribute to the control of pneumo-
coccal disease by reduction of nasopharyngeal
carriage in healthy children. However, long-term
standardised surveillance for nasopharyngeal
carriage, combined with surveillance of isolates
causing invasive and non-invasive disease, will
be necessary.
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